Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag357 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Narendranath Epperla und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, The Ohio State University, Columbus, OH 43201, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, Ethnic and Racial Minorities. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cardinal Health.
Abstract (Originalsprache)
Background
Outcomes may differ among patients with diffuse large B-cell lymphoma (DLBCL) based on race and ethnicity; however, individuals from diverse racial and ethnic backgrounds have historically been underrepresented in clinical trials. This study describes the real-world characteristics, treatment patterns, and outcomes of patients treated with tafasitamab, an anti-CD19 monoclonal antibody for relapsed or refractory (R/R) DLBCL, by race and ethnicity.
Methods
A descriptive subgroup analysis by race and ethnicity was conducted from a retrospective, physician-abstracted medical chart review study. Patients were aged ≥18 years, initiated tafasitamab treatment for R/R DLBCL on/after October 21, 2020, and had ≥4 months follow-up; patients who died during follow-up were included. Data were collected from February 22 to March 29, 2023, and from December 18, 2023 to January 31, 2024.
Results
The analysis included 181 patients: 64.1% White, 22.1% Black or African American, 7.7% Other (race other than White, Black or African American, or unknown), 6.1% were of unknown race; 82.3% non-Hispanic, 17.1% Hispanic, and 0.6% were of unknown ethnicity. The median (Q1-Q3) follow-up time for the overall study population from tafasitamab initiation was 14.7 (8.5-17.1) months and was relatively similar for all subgroups. Most patients (71.8%) received tafasitamab in second-line and this was true across subgroups. Real-world overall response rates (95% CI) were 73.3% (65.2-81.3), 82.5% (70.7-94.3), 74.5% (67.5-81.5), and 67.7% (51.3-84.2) for White, Black or African American, non-Hispanic, and Hispanic patients, respectively.
Conclusions
Findings suggest effectiveness outcomes among patients receiving tafasitamab for R/R DLBCL were consistent across racial and ethnic groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, The Ohio State University, Columbus, OH 43201, United States.
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
- Present address: Southwest Oncology, CommonSpirit Oncology Mercy, Durango, CO 81301, United States.
- Cardinal Health, Dublin, OH 43017, United States.
- Incyte Corporation, Wilmington, DE 19803, United States.
ORCID-Profile: Prathamesh Pathak, Danielle Gentile, Kim Saverno
Förderung
- Cardinal Health
Zitieren
APA
Epperla, N., Nastoupil, L. J., Feinberg, B., Galvin, J., Pathak, P., Amoloja, T., Gentile, D., Asgarisabet, P., & Saverno, K. (2026). Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States. The Oncologist. https://doi.org/10.1093/oncolo/oyag357
Vancouver
Epperla N, Nastoupil LJ, Feinberg B, Galvin J, Pathak P, Amoloja T, et al. Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States. The Oncologist. 2026. doi:10.1093/oncolo/oyag357
BibTeX
@article{Epperla2026,
author = {Epperla, Narendranath and Nastoupil, Loretta J and Feinberg, Bruce and Galvin, John and Pathak, Prathamesh and Amoloja, Theresa and Gentile, Danielle and Asgarisabet, Parisa and Saverno, Kim},
title = {Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag357}
}
EUVIMED